Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

NephroDI Therapeutics Lands Financing to Develop a Treatment for Nephrogenic Diabetes Insipidus, an Orphan Disease

Collaboration with Xontogeny provides funding and key advisory support for early development

NephroDI Therapeutics, Inc., a biopharmaceutical company developing NDI-5033 for the X-linked/congenital form of Nephrogenic Diabetes Insipidus (NDI), announced a seed investment from Xontogeny, LLC to advance their lead program through critical preclinical work.

X-linked NDI affects 1 in 250,000 males in the US and is characterized by profoundly excessive urination of up to 20L (5 gal) per day and frequent complications. NephroDI’s lead product, NDI-5033 is a unique adenosine monophosphate activated kinase (AMPK) activator that can stimulate water reabsorption without causing hypoglycemia, decreasing overall urine output. NDI-5033 is being developed for the congenital form of NDI. The current standard of care for NDI is centered around hydrating with up to 80 glasses of water per day, low sodium diet, diuretics, and non-steroidal anti-inflammatory drugs or NSAIDs which can cause additional kidney damage with chronic use. NDI-5033 is positioned to become a much-needed alternative to these current management measures.

Recommended AI News: Mosyle Sets the First Standard for Apple Device Security in K-12 Schools

“We are excited to collaborate with NephroDI in addressing the unmet need for a treatment of congenital NDI,” said Chris Garabedian, Founder, Chairman and Chief Executive Officer of Xontogeny. “The Xontogeny team is well-suited to support the Company’s goals of benefiting children suffering from NDI.”

Related Posts
1 of 40,355

Congenital NDI manifests at birth and is a life-long condition with a normal life expectancy. NDI patients produce extremely large amounts of dilute urine resulting from an inability of the kidney to respond to vasopressin. Congenital NDI results primarily from mutations in the vasopressin 2 receptor, which is located on the X chromosome. Congenital NDI has a profound impact on children. If hydration is not maintained, it can cause mental retardation and even chronic kidney disease by middle school age. It is considered an orphan condition in the US and Europe. Current management measures are minimally effective and onerous in that they require patients to drink as much fluid as they excrete to prevent dehydration and eat an extremely restricted diet.

Recommended AI News: Mundrisoft partners with a leading US-Based EdTech Company to Accelerate Learning Delivery

“We are thrilled to collaborate with Xontogeny. Their support, consisting of an investment and industry experience, will be especially important in our goal to bring NDI-5033 into clinical trials,” said Rachael Hagan, President and Chief Executive Officer, NephroDI Therapeutics. “We look forward to working with the Xontogeny team as we develop much-needed therapies to treat children suffering from NDI.”

The Board of Directors will be comprised of Chairman, Chris Garabedian, CEO of Xontogeny, Fred Callori, SVP, Corporate Development of Xontogeny, and Rachael Hagan.

Recommended AI News: BlackLine Achieves ISO/IEC 27017 Cloud Security Certification

Comments are closed.